NCT05705492 2026-01-21
Olanzapine for the Management of Cancer Associated Appetite Loss in Patients With Advanced Esophagogastric, Hepatopancreaticobiliary, Colorectal or Lung Cancer
OHSU Knight Cancer Institute
Phase 2 Recruiting
Clinical Trials
8 trialsNCT03118986 2025-10-08
RCT of Olanzapine for Control of CIV in Children Receiving Highly Emetogenic Chemotherapy
The Hospital for Sick Children
Phase 2 Recruiting
NCT06175273 2025-09-18
POINT
University of Kentucky
Phase 2/3 Completed
NCT07035821 2025-06-25
Olanzapine for Prevention of Vomiting in Children and Adolescents Receiving Highly Emetogenic Chemotherapy
Shanghai Children's Medical Center
Phase 3 Not yet recruiting
NCT03578081 2025-04-06
Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy
Alliance for Clinical Trials in Oncology
Phase 3 Completed
NCT06500234 2024-07-15
Nutrition Impact on Immunotherapy of Cancer
Qingdao Central Hospital
Phase 3 Recruiting
NCT02400866 2015-03-27
A Randomized Study of Olanzapine for the Prevention of CINV in Patients Receiving Moderately Emetogenic Chemotherapy
Korean South West Oncology Group
Phase 2 Unknown
NCT00124930 2012-01-19
Study Comparing Olanzapine With Haloperidol for the Relief of Nausea and Vomiting in Patients With Advanced Cancer
AHS Cancer Control Alberta
Phase 3 Terminated